Dolar-Szczasny Joanna, Bucolo Claudio, Zweifel Sandrine, Carnevali Adriano, Rejdak Robert, Załuska Wojciech, Czarnek-Chudzik Aleksandra, Toro Mario Damiano
Department of General Ophthalmology, Medical University of Lublin, Lublin, Poland.
Section of Pharmacology, Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy.
Front Pharmacol. 2021 Apr 30;12:656774. doi: 10.3389/fphar.2021.656774. eCollection 2021.
To evaluate the effect of repeated intravitreal bevacizumab injections on blood-aqueous barrier permeability in eyes with neovascular age-related macular degeneration (AMD). Forty-eight consecutive patients with neovascular AMD received 3 intravitreal bevacizumab injections (1 mg) every 30-40 days. Subjects were followed for a period of 4 months and were examined at baseline, 1 day and 1 month after each injection. A control group comprised of 19 neovascular AMD patients waiting to begin anti-vascular endothelial growth factor (VEGF) therapy. Anterior chamber (AC) inflammation was evaluated with biomicroscopy and laser flare photometry. None of the subjects treated with bevacizumab had detectable ocular inflammation during follow-up. An analysis for variance (ANOVA) of the mixed-effects model has shown neither an effect between treatment and control group ( = 0.921), nor over the time course of the follow-up ( = 0.773). Before treatment, median AC inflammation was 6.7 photons/ms (range: 3.5-18.2 photons/ms). One month after the first, second, and third injections, median laser flare was 6.4, 6.8, and 6.6 photons/ms, respectively, none of which were significantly different from baseline (all > 0.05). Blood-aqueous barrier permeability did not change between injections and was not different from the control group. Inflammation induced by intravitreal bevacizumab was not detected by examination or flare photometry. This suggests that monthly bevacizumab dosing seems to be safe. The absence of AC inflammation could also reflect the known anti-inflammatory properties of anti-VEGF agents.
评估重复玻璃体内注射贝伐单抗对新生血管性年龄相关性黄斑变性（AMD）患者血-房水屏障通透性的影响。48例连续的新生血管性AMD患者每30 - 40天接受3次玻璃体内贝伐单抗注射（1毫克）。对受试者进行4个月的随访，并在基线、每次注射后1天和1个月进行检查。对照组由19例等待开始抗血管内皮生长因子（VEGF）治疗的新生血管性AMD患者组成。通过生物显微镜检查和激光散射光度法评估前房（AC）炎症。在随访期间，接受贝伐单抗治疗的受试者均未检测到眼部炎症。混合效应模型的方差分析（ANOVA）显示，治疗组与对照组之间无效应（P = 0.921），随访期间也无效应（P = 0.773）。治疗前，AC炎症中位数为6.7个光子/毫秒（范围：3.5 - 18.2个光子/毫秒）。在第一次、第二次和第三次注射后1个月，激光散射中位数分别为6.4、6.8和6.6个光子/毫秒，均与基线无显著差异（均P>0.05）。注射之间血-房水屏障通透性未改变，且与对照组无差异。通过检查或散射光度法未检测到玻璃体内贝伐单抗引起的炎症。这表明每月使用贝伐单抗似乎是安全的。AC炎症的缺乏也可能反映了抗VEGF药物已知的抗炎特性。
